Companies /Industrials

Insperity Inc

NYSE: NSP Staffing & Employment Services
$51.62
▼ $0.20 (−0.39%) today
Markets open · 3:04pm ET

Q4 2025 Earnings

Reported Feb 10, 2026, 4:46pm ET · SEC source
$-0.60
Miss −28.89%
EPS · est. $-0.47
$1.7B
Miss −0.62%
Revenue · est. $1.7B
−24.3%
Trailing market
NSP vs S&P since report
1 quarter
Consecutive EPS misses

Market Reaction

% change · around the report
−14%−7%0+7%Feb 10Feb 11report 4:46pm ETearnings−0.0%−9.1%
−14%−7%0+7%Feb 10Feb 11earnings−0.0%−9.1%
NSP −9.1%S&P 500 −0.0%
−14%−7%0+7%Feb 10Feb 11report 4:46pm ETearnings+0.2%−9.1%
−14%−7%0+7%Feb 10Feb 11earnings+0.2%−9.1%
NSP −9.1%NASDAQ +0.2%
−20%0Feb 9Feb 18report 4:46pm ETearnings−1.0%−22.1%
−20%0Feb 9Feb 18earnings−1.0%−22.1%
NSP −22.1%S&P 500 −1.0%
−20%0Feb 9Feb 18report 4:46pm ETearnings−1.2%−22.1%
−20%0Feb 9Feb 18earnings−1.2%−22.1%
NSP −22.1%NASDAQ −1.2%
−10.87%
Day of report
−13.60%
Next session
−16.03%
One week
−27.60%
30 days

S&P 500 over the same 30 days: −3.31%.

Did NSP Beat Earnings? Q4 2025 Results

Insperity closed out fiscal 2025 on a sour note, posting a steeper-than-expected Q4 loss as relentless benefits cost pressures overwhelmed modest top-line growth. The professional employer organization reported adjusted EPS of -$0.60 for the quarter, missing the consensus estimate of -$0.47 by 28.89%, while revenue of $1.67 billion edged 3.4% higher year over year but fell just short of the $1.68 billion Wall Street had anticipated. The core culprit was a sharp deterioration in gross profit, which tumbled 21% to $172.00 million as elevated inpatient, outpatient, and pharmacy cost trends, compounded by large-claim frequency, erased pricing gains from a 2% increase in revenue per worksite employee. Shares slipped roughly 7.6% following the report, reflecting investor frustration with the sustained benefits drag. Management is betting that restructured UnitedHealthcare contracts, tighter client selection, and new growth initiatives will drive a meaningful rebound, guiding full-year 2026 adjusted EPS of $1.69 to $2.72, representing a recovery of 64% to 164% above depressed 2025 levels.

Key Takeaways
  • Elevated benefits costs driven by inpatient, outpatient, and pharmacy trends and large claim frequency
  • 2% increase in revenue per WSEE per month from higher pricing
  • 1% growth in average paid WSEEs to 312,377 in Q4
  • 6% decrease in operating expenses to $218 million in Q4
  • Reduced Workday strategic partnership costs ($10M in Q4 2025 vs $19M in Q4 2024)

“We accomplished the key objective of our year-end transition with a step up in gross profit margin, which we believe positions the company for a significant recovery in profitability this year.”

Insperity CEO, on the earnings call

Forward Guidance & Outlook

For Q1 2026, Insperity guides average WSEEs paid of 303,000–305,000 (down 0.3%–1.0% YoY), adjusted EPS of $1.03–$1.50 (down 4%–34% YoY), and adjusted EBITDA of $81–$111 million (up 9% to down 21% YoY). For full year 2026, the company expects average WSEEs paid of 305,400–314,700 (down 1.5% to up 1.5% YoY), adjusted EPS of $1.69–$2.72 (up 64%–164% YoY), and adjusted EBITDA of $170–$230 million (up 30%–76% YoY). Management expects profitability recovery through pricing and client selection actions, new contract and plan design changes with UnitedHealthcare, operating expense efficiencies, and growth from HR360 and HRScale initiatives. A restructuring charge of approximately $9 million is expected in Q1 2026. The 2026 guidance includes an effective tax rate of 39% for Q1 and 34% for the full year.

NSP YoY Financials

Q4 2025 vs Q4 2024 · SEC filings Q4 2024 Q4 2025
$0$500.0M$1.0B$1.5B$1.6B$1.7BRevenue$218.0M$172.0MGross Profit
$0$500.0M$1.0B$1.5BRevenueGross Profit

Figures from SEC filings and company reports. Not investment advice.